HUE038324T2 - GDF-8 elleni antagonista antitestek és alkalmazásaik ALS és más GDF-8-al kapcsolatos betegségek kezelésében - Google Patents

GDF-8 elleni antagonista antitestek és alkalmazásaik ALS és más GDF-8-al kapcsolatos betegségek kezelésében

Info

Publication number
HUE038324T2
HUE038324T2 HUE11161564A HUE11161564A HUE038324T2 HU E038324 T2 HUE038324 T2 HU E038324T2 HU E11161564 A HUE11161564 A HU E11161564A HU E11161564 A HUE11161564 A HU E11161564A HU E038324 T2 HUE038324 T2 HU E038324T2
Authority
HU
Hungary
Prior art keywords
gdf
als
treatment
antibodies against
associated disorders
Prior art date
Application number
HUE11161564A
Other languages
English (en)
Inventor
Frank S Walsh
Margaret M Zaleska
David S Howland
Erika L F Holzbaur-Howland
Lioudmila Tchistiakova
Riyez Karim
Pamela Kelley
Xiang-Yang Tan
Seung Poon Kwak
Karen Wallace
Nicholas Weber
Menelas N Pangalos
Original Assignee
Wyeth Llc
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc, Univ Pennsylvania filed Critical Wyeth Llc
Publication of HUE038324T2 publication Critical patent/HUE038324T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
HUE11161564A 2005-08-19 2006-08-14 GDF-8 elleni antagonista antitestek és alkalmazásaik ALS és más GDF-8-al kapcsolatos betegségek kezelésében HUE038324T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70970405P 2005-08-19 2005-08-19

Publications (1)

Publication Number Publication Date
HUE038324T2 true HUE038324T2 (hu) 2018-10-29

Family

ID=37606840

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE06801434A HUE025240T2 (hu) 2005-08-19 2006-08-14 GDF-8 elleni antagonista ellenanyagok, valamint ezek alkalmazása az ALS és más, a GDF-8-hoz kapcsolódó rendellenességek kezelésében
HUE11161564A HUE038324T2 (hu) 2005-08-19 2006-08-14 GDF-8 elleni antagonista antitestek és alkalmazásaik ALS és más GDF-8-al kapcsolatos betegségek kezelésében

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE06801434A HUE025240T2 (hu) 2005-08-19 2006-08-14 GDF-8 elleni antagonista ellenanyagok, valamint ezek alkalmazása az ALS és más, a GDF-8-hoz kapcsolódó rendellenességek kezelésében

Country Status (16)

Country Link
US (7) US7888486B2 (hu)
EP (3) EP2407486B1 (hu)
JP (2) JP5415071B2 (hu)
CN (2) CN103450359B (hu)
AU (1) AU2006283725B2 (hu)
BR (1) BRPI0614893A2 (hu)
CA (1) CA2619491C (hu)
DK (2) DK1915397T3 (hu)
ES (2) ES2659114T3 (hu)
HK (1) HK1119716A1 (hu)
HU (2) HUE025240T2 (hu)
MX (1) MX2008002367A (hu)
PL (2) PL2407486T3 (hu)
PT (2) PT1915397E (hu)
SI (2) SI1915397T1 (hu)
WO (1) WO2007024535A2 (hu)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR042545A1 (es) 2002-12-20 2005-06-22 Amgen Inc Agentes ligantes que inhiben la miostatina
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
PT1915397E (pt) 2005-08-19 2015-04-30 Univ Pennsylvania Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8
US9050005B2 (en) 2005-08-25 2015-06-09 Synapse Biomedical, Inc. Method and apparatus for transgastric neurostimulation
JP5052517B2 (ja) * 2005-10-06 2012-10-17 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8676323B2 (en) * 2006-03-09 2014-03-18 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US20080097153A1 (en) * 2006-08-24 2008-04-24 Ignagni Anthony R Method and apparatus for grasping an abdominal wall
KR101123531B1 (ko) 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
TWI432449B (zh) 2007-02-02 2014-04-01 Acceleron Pharma Inc 衍生自ＡｃｔＲＩＩＢ的變體與其用途
US9079016B2 (en) * 2007-02-05 2015-07-14 Synapse Biomedical, Inc. Removable intramuscular electrode
US9820671B2 (en) * 2007-05-17 2017-11-21 Synapse Biomedical, Inc. Devices and methods for assessing motor point electromyogram as a biomarker
MX342551B (es) 2007-09-26 2016-10-04 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US8428726B2 (en) 2007-10-30 2013-04-23 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system
WO2009059033A1 (en) * 2007-10-30 2009-05-07 Synapse Biomedical, Inc. Method of improving sleep disordered breathing
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
CN101489288B (zh) 2008-01-16 2011-04-20 华为技术有限公司 演进分组网络中电路域业务的处理方法、系统及相关设备
NZ602884A (en) 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP3415161A1 (en) 2008-06-26 2018-12-19 Acceleron Pharma Inc. The use of an actriib antagonist for the treatment of anemia
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
AR074777A1 (es) * 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
EP3275900A1 (en) * 2009-04-27 2018-01-31 Novartis AG Compositions and methods for increasing muscle growth
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
PT2569013T (pt) * 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
US11103514B2 (en) * 2010-05-26 2021-08-31 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
CA2803937A1 (en) * 2010-06-30 2012-01-05 Mount Sinai Hospital Reagents and methods for diagnosing conditions associated with hydroxylated hif 1-a
PT2644698T (pt) 2010-11-17 2018-01-31 Chugai Pharmaceutical Co Ltd Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR102048189B1 (ko) 2011-11-14 2019-11-25 리제너론 파아마슈티컬스, 인크. Ｇｄｆ8 및/또는 액티빈 ａ를 특이적으로 길항함으로써 근육량과 근육 강도를 증가시키는 조성물 및 방법
JP6433889B2 (ja) 2012-06-15 2018-12-05 ファイザー・インク Ｇｄｆ−８に対する改善された拮抗抗体およびその使用
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
RU2729831C2 (ru) 2012-08-24 2020-08-12 Чугаи Сейяку Кабусики Кайся ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ
RS62009B1 (sr) 2012-09-13 2021-07-30 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
MX2015005874A (es) 2012-11-09 2015-09-10 Pfizer Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
LT2981822T (lt) 2013-05-06 2020-12-28 Scholar Rock, Inc. Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
SG11201602261VA (en) 2013-09-27 2016-04-28 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
WO2015070076A2 (en) * 2013-11-08 2015-05-14 President And Fellows Of Harvard College Methods and compositions for rejuvenating neuromuscular junctions
AU2015269333B2 (en) 2014-06-04 2020-05-07 Acceleron Pharma, Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
EP3142413A4 (en) 2014-06-24 2017-06-21 Huawei Technologies Co. Ltd. Method, device and system for saving voice resource
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
AU2015365167B2 (en) 2014-12-19 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN114773469A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Ｉｌ−６関連疾患治療用組成物
WO2016154601A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
MX2017013267A (es) 2015-04-15 2018-08-15 Regeneron Pharma Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8).
EP3922645A1 (en) 2015-09-15 2021-12-15 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3004288A1 (en) 2015-12-28 2017-07-06 Nobuyuki Tanaka Method for promoting efficiency of purification of fc region-containing polypeptide
CA3010799A1 (en) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
US10287345B2 (en) * 2016-01-08 2019-05-14 Scholar Rock, Inc. Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
RU2746754C2 (ru) 2016-03-14 2021-04-20 Чугаи Сейяку Кабусики Кайся Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
KR20230169484A (ko) 2016-06-13 2023-12-15 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
MX2018014375A (es) 2016-06-17 2019-04-22 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y metodos de uso.
CA2971303A1 (en) 2016-06-21 2017-12-21 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019169283A1 (en) 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
JP2022512346A (ja) 2018-12-18 2022-02-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド レプチン受容体、ｇｄｆ８、およびアクチビンａに対するアンタゴニストを使用して、体重および除脂肪筋肉量を増やすための組成物および方法
US11471683B2 (en) 2019-01-29 2022-10-18 Synapse Biomedical, Inc. Systems and methods for treating sleep apnea using neuromodulation
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
WO2020261178A1 (en) 2019-06-27 2020-12-30 Pfizer Inc. Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
RU2710267C1 (ru) * 2019-09-06 2019-12-25 Александр Александрович Яковенко Способ скрининга саркопении у пациента, получающего лечение программным гемодиализом
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
AU643435B2 (en) 1989-04-28 1993-11-18 Riker Laboratories, Inc. Dry powder inhalation device
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
SE9502800D0 (sv) 1995-08-10 1995-08-10 Astra Ab Disposable inhaler
US5853723A (en) 1995-09-21 1998-12-29 University Of Utah Research Foundation Targeting of peg antibody conjugates to islet cells
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
PT2045322E (pt) 1997-07-14 2015-10-16 Université de Liège Musculatura dupla em mamíferos
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
AU8921698A (en) 1997-08-29 1999-03-16 Human Genome Sciences, Inc. Follistatin-3
US6102454A (en) 1997-09-15 2000-08-15 Robert Bosch Gmbh Motor vehicle door lock arrangement
WO1999024618A1 (en) 1997-11-10 1999-05-20 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
AU2586199A (en) 1998-02-05 1999-08-23 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
EP1075272B1 (en) 1998-05-06 2009-07-15 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
NZ513642A (en) 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
AU778470B2 (en) 1999-07-20 2004-12-09 Pharmexa A/S Method for down-regulating GDF-8 activity
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CU23007A1 (es) 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL375045A1 (en) 2002-02-21 2005-11-14 Wyeth Gasp1: a follistatin domain containing protein
WO2003072714A2 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2004245025A1 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
DE602004030341D1 (de) 2003-06-23 2011-01-13 Genetics Inst Llc Antikörper gegen interleukin-22 und verwendungen dafür
BRPI0609439A2 (pt) 2005-03-23 2010-04-06 Wyeth Corp detecção de uma resposta imunológica a agentes moduladores de gdf-8
EP1864138A2 (en) 2005-03-23 2007-12-12 Wyeth Detection of gdf-8 modulating agents
PT1915397E (pt) 2005-08-19 2015-04-30 Univ Pennsylvania Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8

Also Published As

Publication number Publication date
PT2407486T (pt) 2018-02-21
JP2009504185A (ja) 2009-02-05
US20120003212A1 (en) 2012-01-05
US7888486B2 (en) 2011-02-15
EP2407486B1 (en) 2017-11-22
US8956608B2 (en) 2015-02-17
PL2407486T3 (pl) 2018-05-30
JP2012244998A (ja) 2012-12-13
EP2407486A1 (en) 2012-01-18
AU2006283725B2 (en) 2012-02-16
US7910107B2 (en) 2011-03-22
US20090285827A1 (en) 2009-11-19
CN101379086B (zh) 2013-07-17
CN101379086A (zh) 2009-03-04
US20130156767A1 (en) 2013-06-20
US9926368B2 (en) 2018-03-27
US20140086920A1 (en) 2014-03-27
PT1915397E (pt) 2015-04-30
EP3327033A1 (en) 2018-05-30
US20120016106A1 (en) 2012-01-19
EP1915397A2 (en) 2008-04-30
SI1915397T1 (sl) 2015-05-29
ES2659114T3 (es) 2018-03-13
MX2008002367A (es) 2008-03-18
DK2407486T3 (en) 2018-02-19
AU2006283725A1 (en) 2007-03-01
JP5415071B2 (ja) 2014-02-12
SI2407486T1 (en) 2018-04-30
US20150152176A1 (en) 2015-06-04
US20070087000A1 (en) 2007-04-19
US8496934B2 (en) 2013-07-30
DK1915397T3 (en) 2015-04-20
CA2619491A1 (en) 2007-03-01
CN103450359A (zh) 2013-12-18
HUE025240T2 (hu) 2016-03-29
CA2619491C (en) 2016-05-10
CN103450359B (zh) 2018-07-24
EP1915397B1 (en) 2015-01-14
PL1915397T3 (pl) 2015-08-31
US8372625B2 (en) 2013-02-12
WO2007024535A2 (en) 2007-03-01
US8349327B2 (en) 2013-01-08
WO2007024535A3 (en) 2007-04-19
BRPI0614893A2 (pt) 2010-03-30
ES2534760T3 (es) 2015-04-28
HK1119716A1 (en) 2009-03-13

Similar Documents

Publication Publication Date Title
HK1119716A1 (en) Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders gdf-8 als gdf-8
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
ZA200708332B (en) Antibodies against CCR5 and uses thereof
EP1963372A4 (en) ANTI-MN ANTIBODIES AND METHODS OF USE
PL1859004T3 (pl) Środki sieciujące kompozycję opracowania odwiertu oraz ich zastosowania
IL197831A0 (en) Human antibodies that bind cxcr4 and uses thereof
HK1126212A1 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2097534A4 (en) HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF
IL207688A0 (en) Methods of treating skin disorders using an il-31ra antagonist
EP1928271A4 (en) STABLE ACIDIC BEVERAGE EMULSIONS AND METHOD FOR THE PRODUCTION THEREOF
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
IL182943A0 (en) Ovr110 antibody compositions and methods of use
ZA200904657B (en) Human antibodies that bind CD70 and uses thereof
EP1913390A4 (en) ASSAY PARTICLES AND METHODS OF USE THEREOF
IL196861A0 (en) Antibodies against ccr5 and uses thereof
IL186325A0 (en) Tizanidine compositions and methods of treatment using the compositions
EP1838730A4 (en) PAN-HER ANTAGONISTS AND METHODS OF USE
IL185791A0 (en) Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease
HK1121378A1 (en) Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
WO2006116311A3 (en) Opioid receptor agonist compounds and their use in treatment of pain
GB2431946B (en) Injectors for use in wellbores and methods of their use
HK1127069A1 (en) Antagonists against interaction of pf4 and rantes
EP2045245A4 (en) IRREVERSIBLE TYROSINE KYNASES INHIBITORS AND METHODS OF PREPARATION AND USES THEREOF
IL186277A0 (en) Dnt-maleate and methods of preparation thereof
EP1969008A4 (en) ANTIBODIES TO INTERLEUKIN-22 BINDING PROTEIN AND ITS APPLICATIONS IN THE TREATMENT OF METABOLISM DISORDERS